Hamburg Edoxaban for Anticoagulation in COVID-19 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

September 6, 2022

Study Completion Date

January 15, 2023

Conditions
Covid19
Interventions
DRUG

Anticoagulation Agents (Edoxaban and/or high dose LMWH)

In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until

DRUG

Low dose Low molecular weight heparin or Placebo

In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban

Trial Locations (10)

Unknown

UK Aachen, Aachen

Universitätsklinikum Augsburg, Augsburg

Universitätsklinikum Düsseldorf, Düsseldorf

Universitätsklinikum Freiburg, Freiburg im Breisgau

Asklepios Klinik Altona, Hamburg

Asklepios Klinik Barmbek, Hamburg

Asklepios Klinik St. Georg, Hamburg

Universitärsklinikum Hamburg-Eppendorf, Hamburg

Medizinische Hochschule Hannover, Hanover

TU München Klinikum rechts der Isar, München

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT04542408 - Hamburg Edoxaban for Anticoagulation in COVID-19 Study | Biotech Hunter | Biotech Hunter